Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Intravenous Immunoglobulin (IVIg) Markets, 2024 - Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIG Market

This image opens in the lightbox

News provided by

Research and Markets

12 Oct, 2017, 15:15 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, October 12, 2017 /PRNewswire/ --

The "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report has been added to Research and Markets' offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

The report profiles 24 companies including many key and niche players such as:

  • Bharat Serums and Vaccines Limited (India)
  • Biotest AG (Germany)
  • China Biologic Products, Inc. (China)
  • CSL Limited (Australia)
  • Grifols, S.A. (Spain)
  • Guizhou Taibang Biological Products Co., Ltd (China)
  • Hualan Biological Engineering Inc. (China)
  • Kedrion S.p.A. (Italy)
  • LFB Group (France)
  • Octapharma AG (Switzerland)
  • Shanghai RAAS Blood Products Co., Ltd. (China)
  • Shire plc (Ireland)
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)

Key Topics Covered: 

1. INDUSTRY OVERVIEW
Immunoglobulins to See Steady Growth
Intravenous Immunoglobulin
A Proliferating Biologic
Application Areas
A Brief Review
Market Outlook
Growth Drivers and Market Challenges
Competitive Scenario
Grifols Continues to Consolidate Market Position
Comparison of Select Drugs and Approved Indications
CSL Sees Robust Growth in Immunoglobulin Franchise
Shire Continues to Invest Big in Immunoglobulins
Bivigam Changes Hands Consequent to Unexpected Turn of Events

2. MARKET TRENDS
Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth of Immunoglobulins
Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market
The Mainstay of PI Therapy
Subcutaneous IG Formulations Gain Therapeutic Foothold
Hyperimmune Globulin
Taking IVIg Therapy a Step Ahead
Unsuccessful Clinical Trials for Alzheimer's
A major Setback for IVIg Market
Synthetic Replacements to IVIg Therapy
IVIg Therapy
Home-based vs. Outpatient Settings
Per Capita Consumption Rate Varies Across Countries
Favorable Reimbursement and High Usage make US the Largest Consumer
Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
Aging Global Population: Major Opportunity Indicator
Improving Healthcare Expenditure to Foster Growth

3. PLASMA PROTEINS - AN OVERVIEW
Plasma and Plasma Derivatives Continue to Dominate Blood Components Market
Regulations Exercise a Tight Rein over Plasma Therapy & Immunoglobulins

4. THERAPY OVERVIEW
Immunoglobulins Overview
IVIg and SCIg: A Face-off!
Cost of Product and Treatment
Side-Effects
Frequency of Treatment
Safety Considerations
Patient Response to Treatment Varies
Site of Care
IVIg Therapy Introduction
Intravenous Immunoglobulin
Mechanism of IVIg Action
IVIg Dosage and Treatment Response Time
Common IVIg Intravenous Dosing Recommendations by Indication
Complications and Side Effects of Using IVIg
Precautions to be Undertaken
Intravenous Immunoglobulin
Indications
FDA Approved Indications for IVIg
Off-Label Usage of IVIg
Select Off-Label Indications for IVIg
Applications by Medical Specialty
Neurology
Hematology
Immunology
Dermatology
Nephrology, Rheumatology, Ophthalmology, and Other Diseases

5. RECENT INDUSTRY ACTIVITY
LFB Group's 10% IVIg Gains More Approvals in Europe
CSL Acquires Majority Stake in Ruide
Baxter Acquires Claris Injectables
ADMA Biologics Takes Over BTBU
Green Cross Receives FDA Complete Response Letter for IVIG-SN
China Biologic Products Completes Acquisition of Guizhou Taibang
ProMetic Completes Patient Enrolment for Phase III Pivotal IVIG Trial
Kroger Combines Axium Pharmacy and Modern HC
Shire Acquires Baxalta
FDA Accepts BLA for IVIG-SN from Green Cross
Kedrion Bags US Commercial Rights to BIVIGAM
China Biologic Products to Commence Clinical Trials on Next- Gen IVIG Products
FDA Clears ProMetic's IND for IVIg
LFB Obtains Initial Market Authorizations for 10% Liquid IVIg in Europe
Baxter Divests its BioScience Division
Emergent BioSolutions Acquires Cangene
CMS Begins Evaluation of Payment for In-home IVIG Administration

6. FOCUS ON SELECT PLAYERS

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 24 (including Divisions/Subsidiaries 32)

  • The United States (11)
  • Canada (2)
  • Japan (1)
  • Europe (8)
    • France (1)
    • Germany (1)
    • The United Kingdom (2)
    • Italy (1)
    • Spain (1)
    • Rest of Europe (2)
  • Asia-Pacific (Excluding Japan) (9)
  • Latin America (1)

For more information about this report visit https://www.researchandmarkets.com/research/z6rgb6/intravenous

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.